On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery

  • Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking results
  • This study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent study
  • The study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine pouch performance to leading brands

Zacks Small Cap Research recently did a deep dive on Lexaria Bioscience (NASDAQ: LEXX) and its contribution to alternative nicotine delivery. Its evaluation acknowledged that the global tobacco market is currently valued at $818 billion, mainly sustained by over 1.1 billion smokers. Smoking has been attributed to cancer, heart disease, stroke, and lung diseases, among other life-threatening conditions. In the United States alone, smoking is responsible for over 480,000 deaths every year and 8 million deaths worldwide, according to the World Health Organization (“WHO”) (https://ibn.fm/Y1CL0). 

Zacks also noted that according to the U.S. Food and Drug Administration (“FDA”), over 70% of U.S. smokers would like to quit. However, the nicotine replacement therapies (“NRT”) available in the market today, which include patches and gums, fail due to slow and low levels of nicotine delivered to the nicotine receptors in the brain, forcing affected persons to revert to smoking.

Tobacco companies have had to grapple with this challenge, compounded by legislation such as classifying products with more than 4mg of nicotine per dose as prescription drugs, as is the case with Canada. According to Zacks, there has never been such an immense need for a practical option for nicotine delivery that can bypass the existing hurdles already put in place, and deliver sufficient nicotine to deter smoking. 

Lexaria has made a name for itself with its patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing. Its subsidiary, Lexaria Nicotine Corp., has advanced its nicotine delivery research, building on its patented DehydraTECH(TM) technology. In a recent animal study highlighted by Zacks, NIC-A21-1, the company evaluated the improved methods of nicotine absorption as an alternative to combustible tobacco products in what was a very successful study.

Lexaria began research on the technology back in 2018. The initial investigation demonstrated effective delivery of nicotine to the central nervous system (“CNS”) in a rodent study, with nicotine polacrilex achieving 195% greater delivery and four-fold more rapid delivery across the blood-brain barrier (“BBB”) compared with the control. Zacks pointed this out as one of Lexaria’s primary strengths and a critical step towards pushing DehydraTECH to market. 

Fast forward to 2021, and Lexaria, working together with an independent testing laboratory, conducted an additional study on canines.

This analysis evaluated nicotine benzoate and polacrilex plasma levels in these animals comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The study involved 40 anaesthetized male beagle dogs that were assessed, and blood samples were taken every few minutes over the course of two hours.

In what Zacks also defined as another strength for Lexaria, the results from this study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both 8 minutes and again at 30 minutes. It was further noted that in just 4 minutes after the pouch was placed in the mouth, the DehydraTECH-nicotine had reached a higher delivery level than the generic achieved at any point during the study.

While announcing the results, Chris Bunka, the Chief Executive Officer of Lexaria, noted, “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral pouch formulations in this study. Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction” (https://ibn.fm/TSZqq). 

He further added, “Performance gains of this magnitude could be of great significance in enabling the oral pouch product category to offer improved nicotine satiety and effectiveness, with a goal of one day rendering pulmonary administration practices like smoking and vaping as obsolete.”

Zacks acknowledges that the success of this study will serve as the foundation for a more extensive investigation among human volunteers. This human trial will compare the DehydraTECH-nicotine pouch performance to leading brands, including Zyn (a product from Swiss tobacco company, Swedish Match) and ON! (a product from Altria Group). The research, which is currently in the design phase, will be independently funded with existing capital, with the announcement of further details being made as they become available.

Lexaria is optimistic that this human study will yield more positive findings to those evidenced in the previous 2018 animal study and align with the just-concluded dog study. With the nicotine oral pouch market ranked among the fastest-growing nicotine sectors globally, Lexaria believes that DehydraTECH is ideally suited and could revolutionize the nicotine industry as the first practical, reduced risk category to challenge smoking tobacco successfully.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered